In Brief C. Ola Landgren named the inaugural leader of experimental therapeutics at Sylvester October 30, 2020Vol.46 No.41
In Brief Beth Gaffney named VP of U.S. and global business development at NCCN October 30, 2020Vol.46 No.41
In Brief Reagan-Udall receives $250,000 from Rockefeller Foundation for COVID-19 Diagnostics Evidence Accelerator October 30, 2020Vol.46 No.41
In Brief Global Cancer Institute extends programs for underserved cancer patients to Bangladesh October 30, 2020Vol.46 No.41
Racism is a malignancy: Ibram X. Kendi reflects on his cancer experience October 30, 2020Vol.46 No.41By Alexandria Carolan
Conversation with The Cancer Letter Owkin’s AI model provides proof of concept that machine learning can predict gene expression across cancer types October 30, 2020Vol.46 No.41By Matthew Bin Han Ong
Drugs & Targets Venclexta combination receives FDA approval for untreated AML October 23, 2020Vol.46 No.40
Drugs & Targets Tagrisso receives FDA Priority Review for adjuvant treatment of early-stage EGFR-mutated lung cancer October 23, 2020Vol.46 No.40
